P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Update

Posted by Brenda Bartman on May 29th, 2026

P3 Health Partners Inc. (NASDAQ:PIII – Get Free Report) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 283,541 shares, an increase of 293.3% from the April 30th total of 72,094 shares. Based on an average trading volume of 6,174,785 shares, the short-interest ratio is presently 0.0 days. Approximately 4.8% of the shares of the company are sold short.

P3 Health Partners Price Performance

Shares of PIII stock traded down $2.54 during midday trading on Friday, reaching $13.94. 57,003 shares of the company traded hands, compared to its average volume of 819,361. The firm’s 50 day simple moving average is $4.83 and its two-hundred day simple moving average is $4.08. The firm has a market cap of $100.89 million, a PE ratio of -0.36 and a beta of 0.48. P3 Health Partners has a 1-year low of $1.52 and a 1-year high of $16.89.

P3 Health Partners (NASDAQ:PIII – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of ($4.85) by $5.17. The business had revenue of $386.39 million for the quarter, compared to analyst estimates of $391.45 million. P3 Health Partners had a negative net margin of 8.57% and a negative return on equity of 302.33%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on PIII. Lake Street Capital restated a “buy” rating and set a $14.00 target price (up from $4.00) on shares of P3 Health Partners in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of P3 Health Partners in a research report on Tuesday, April 21st. UBS Group set a $14.00 price target on shares of P3 Health Partners in a research note on Friday, May 15th. Finally, TD Cowen restated a “hold” rating and issued a $14.00 price objective (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $14.00.

View Our Latest Research Report on PIII

Institutional Investors Weigh In On P3 Health Partners

A hedge fund recently bought a new stake in P3 Health Partners stock. Lido Advisors LLC bought a new position in shares of P3 Health Partners Inc. (NASDAQ:PIII – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners at the end of the most recent quarter. Institutional investors and hedge funds own 7.75% of the company’s stock.

About P3 Health Partners

(Get Free Report)

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.

Receive News & Ratings for P3 Health Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for P3 Health Partners and related companies with MarketBeat.com's FREE daily email newsletter.